CN111751555A - Application of H factor antibody in preparation of detection kit - Google Patents

Application of H factor antibody in preparation of detection kit Download PDF

Info

Publication number
CN111751555A
CN111751555A CN202010646848.7A CN202010646848A CN111751555A CN 111751555 A CN111751555 A CN 111751555A CN 202010646848 A CN202010646848 A CN 202010646848A CN 111751555 A CN111751555 A CN 111751555A
Authority
CN
China
Prior art keywords
cancer
factor
antibody
cerebral
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010646848.7A
Other languages
Chinese (zh)
Inventor
朱梅珍
刘颖冰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Yijue Biotechnology Co ltd
Original Assignee
Shanghai Yijue Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yijue Biotechnology Co ltd filed Critical Shanghai Yijue Biotechnology Co ltd
Priority to CN202010646848.7A priority Critical patent/CN111751555A/en
Publication of CN111751555A publication Critical patent/CN111751555A/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Abstract

The invention provides an application of a factor H antibody in preparing a kit for detecting peripheral serum, whole blood or peripheral blood for diagnosing heart or cerebral thrombosis, heart or cerebral infarction, cerebral hemorrhage, heart or cerebral embolism, tumor, bacterial infection, viral infection or tumor. The invention coats the H factor monoclonal antibody or the H factor monoclonal antibody and the polyclonal antibody, combines colloidal gold with the polyclonal antibody, can improve the sensitivity of the kit, can be used together with the polyclonal antibody, and is applied to immunoturbidimetry (immunotransmission turbidimetry, immunonephelometry, immunolatex turbidimetry), ELISA, chemiluminescence, microfluidic chip method, colloidal gold percolation method and chromatography. The invention also provides a kit, which adopts a method of H factor antigen-antibody (comprising monoclonal antibody and polyclonal antibody) combination reaction for detection, and can be applied to diagnosis of heart or cerebral thrombus heart or cerebral infarction cerebral hemorrhage heart or cerebral embolism, bacterial infection or virus infection and tumor.

Description

Application of H factor antibody in preparation of detection kit
Technical Field
The invention belongs to the field of bioengineering, and relates to a kit, in particular to application of a H factor antibody in preparing a kit for detecting peripheral serum, whole blood or peripheral blood for diagnosing heart or cerebral thrombosis, heart or cerebral infarction, cerebral hemorrhage, heart or cerebral embolism, bacterial infection, viral infection, tumors such as thyroid cancer, liver cancer, stomach cancer, uterine cancer, cervical cancer, lung cancer, breast cancer, esophageal cancer, nasopharyngeal cancer, prostatic cancer, colorectal cancer, renal cancer, pancreatic cancer and bladder cancer.
Background
Serum factor H is a glycoprotein with a molecular weight of about 150kDa, which is synthesized and secreted mainly by liver, and furthermore, renal mesangial cells, podocytes, renal tubular epithelial cells, monocytes and the like can also be synthesized, and the normal serum concentration is 0.35-0.59 g/L. Factor H primarily inhibits the overactivation of the alternative complement pathway, thereby protecting host cells from damage. In addition, the H factor can be combined with fragments, DNA, histone and other components of the apoptotic cell to eliminate the apoptotic cell.
The H factor kit is originally used for diagnosing diseases caused by peripheral blood H factor reduction, is occasionally found to be relevant to diagnosis of heart or cerebral thrombosis, heart or cerebral infarction, cerebral hemorrhage and heart or cerebral embolism in screening of hundreds of antibodies, and is also relevant to diagnosis indexes of gram-positive bacteria, gram-negative bacteria, virus infection and tumor diagnosis such as thyroid cancer, liver cancer, gastric cancer, uterine cancer, cervical cancer, lung cancer, breast cancer, esophagus cancer, nasopharyngeal carcinoma, prostate cancer, colorectal cancer, kidney cancer, pancreatic cancer and bladder cancer.
Disclosure of Invention
The invention aims to provide application of an H factor antibody in preparing a kit for detecting peripheral serum, whole blood or peripheral blood for diagnosing heart or cerebral thrombosis, heart or cerebral infarction, cerebral hemorrhage, heart or cerebral embolism, bacterial infection, viral infection or tumor, and the application aims to solve the technical problems that the means for diagnosing the heart or cerebral thrombosis, the heart or cerebral infarction, the cerebral hemorrhage, the heart or cerebral embolism, bacterial infection, thyroid cancer, liver cancer, gastric cancer, uterine cancer, cervical cancer, lung cancer, breast cancer, esophagus cancer, nasopharyngeal carcinoma, prostatic cancer, colon cancer, rectal cancer, kidney cancer, pancreatic cancer and bladder cancer or viral infection is limited and the time is long in the prior art.
The invention provides an application of a factor H antibody in preparing a kit for detecting peripheral serum, whole blood or peripheral blood for diagnosing heart or cerebral thrombosis, heart or cerebral infarction, cerebral hemorrhage, heart or cerebral embolism, bacterial infection or virus infection, or tumor.
Further, the tumor is thyroid cancer, liver cancer, stomach cancer, uterine cancer, cervical cancer, lung cancer, breast cancer, esophageal cancer, nasopharyngeal cancer, prostatic cancer, colon cancer, rectal cancer, kidney cancer, pancreatic cancer or bladder cancer.
Furthermore, the kit comprises a detection plate, a rabbit anti-H factor antibody, a goat anti-H factor antibody conjugate marked by colloidal gold, a confining liquid, a washing liquid, a positive reference product and a negative reference product, wherein the detection plate consists of a plastic box bottom box, a water absorption layer is arranged in the plastic box bottom box, a nitrocellulose membrane is arranged on the water absorption layer, a filter screen is covered on the nitrocellulose membrane, a plastic box surface cover is arranged on the filter screen, a detection reaction hole is arranged in the center of the plastic box surface cover, the rabbit anti-H factor antibody and the goat anti-H factor antibody conjugate marked by colloidal gold are dotted on the nitrocellulose membrane corresponding to the detection reaction hole, the confining liquid is a phosphate solution containing albumin, the pH value of the phosphate solution is 7.0-7.5, and the weight percentage of bovine serum albumin in the phosphate solution is 1.0%, the washing solution is a Tris-HCl solution containing Tween-20, the pH of the Tris-HCl solution is 7.0-7.5, the weight percentage of the Tween-20 in the Tris-HCl solution is 0.05%, the mass of the goat anti-H factor antibody in each milliliter of colloidal gold conjugate is 700 mg, and the positive reference substance is the H factor antigen with the concentration of more than 508 mg/L.
Further, the detection is carried out by colloidal gold filtration, chromatography or chemiluminescence.
Furthermore, ELISA method, immunoturbidimetry, immunotransmission turbidimetry, immunoscattering turbidimetry or immunolatex enhanced turbidimetry is adopted for carrying out clinical examination and routine detection.
Furthermore, a micro-fluidic chip is adopted for detection.
Furthermore, the rabbit anti-H factor antibody is a monoclonal antibody or a polyclonal antibody.
The invention also provides a kit, which adopts H factor antigen-antibody combination reaction for detection.
Furthermore, the rabbit anti-H factor antibody is a monoclonal antibody or a polyclonal antibody, so that the sensitivity and the accuracy of the reagent are improved (comprising the monoclonal antibody or the polyclonal antibody of a mouse, a rabbit, a sheep or a horse).
The detection principle of the invention is as follows: binding reaction of H factor antibody and H factor antigen in serum.
Compared with the prior art, the invention has remarkable technical progress. The kit can be used for detecting H factor antigen in human serum samples, and can be used for diagnosing heart or cerebral thrombosis, heart or cerebral infarction, cerebral hemorrhage, heart or cerebral embolism, bacterial infection or virus infection and tumors such as thyroid cancer, liver cancer, gastric cancer, uterine cancer, cervical cancer, lung cancer, breast cancer, esophageal cancer, nasopharyngeal cancer, prostatic cancer, colorectal cancer, renal cancer, pancreatic cancer and bladder cancer. The kit can receive a detection report within 1 to 5 minutes, and has accurate and convenient detection result.
Detailed Description
Example 1 preparation of a kit
1.1 preparation process of colloidal gold conjugate;
1.1.1 preparing colloidal gold;
1.1.1.10.05% gold chloride solution 300 ml, heating to boil;
1.1.1.2 add 3.6 ml of 5.0% trisodium citrate;
1.1.1.3, continuously heating and boiling for 15 minutes, stopping heating, cooling to room temperature, and recovering the volume to the original volume by using distilled water;
1.1.2 labeling with colloidal gold;
1.1.2.1 colloidal gold 100 mL;
1.1.2.2 adding 2.4 ml of 1.0% anhydrous sodium carbonate solution, and adjusting the pH value to 6.4-7.2;
1.1.2.3 adding 2.5 mL goat anti-H factor antibody (1.0mg/mL), standing at room temperature for 30 min;
1.1.2.4 stirring and adding 10XTris-HCl20 ml to regulate pH to 7.2-7.5;
1.1.2.5 stirring and adding 2 g of BSA, 1 g of PEG20000 and 0.2 ml of ProClin-300;
1.2 detection board preparation process;
1.2.1 assembling a detection plate, taking a plastic box bottom cover, placing a water absorption layer, placing a nitrocellulose membrane on the water absorption layer, covering a plastic box surface cover, and compressing;
1.2.2 detection of Point antibodies: rabbit anti-factor H antibody (1.0mg/mL)1.0 mL 1.0M NaHCO was added30.1 ml, and mixing evenly;
1.2.3 taking 2.0uL of detection point antibody, and adding the detection point antibody on a nitrocellulose membrane at the center of a reaction hole of the detection plate to prepare a detection plate;
1.3 preparing sealing liquid and washing liquid;
1.3.1 preparing a confining liquid, 1.0 percent of bovine serum albumin and 0.02 MpH7.0-7.5 phosphate solution;
1.3.2 preparing a washing solution, 0.05 percent of Tween-20 and 0.05 MpH7.0-7.5 of Tris-HCl solution;
1.4 determining a normal reference range, and selecting a sample with the H factor antigen content of about 508mg/L as sensitivity detection because the method is qualitative detection and the detection point of the sample H factor antigen content in the normal reference range does not develop color based on the H factor antigen content of 274 mg/L-508 mg/L in the normal reference range of the H factor antigen determination kit;
1.4.1 methods of experiment:
1. before use, the reagent and the sample are taken out, and are placed for 15-30 minutes at room temperature to be recovered to the room temperature;
2. taking out the detection plate;
3. adding 2 drops of sealing liquid into the center of a reaction hole of the detection plate until the sealing liquid completely permeates;
4. adding 40 microliters of the sample to be detected into the center of the reaction hole of the detection plate by using a pipettor until the sample completely permeates into the reaction hole;
5. adding 4 drops of washing liquid into the center of the reaction hole of the detection plate until the washing liquid completely permeates into the reaction hole;
6. adding 3 drops of colloidal gold conjugate in the center of the reaction hole of the detection plate until the colloidal gold conjugate completely permeates;
7. adding 4 drops of washing liquid into the center of the reaction hole of the detection plate, and observing the result visually after the washing liquid completely permeates;
[ interpretation of test results ]
When a user performs sample detection, the following situations may occur:
a. a red spot is arranged at the center detection point of the reaction hole of the detection plate, and a positive result is obtained;
b. the detection point at the center of the reaction hole of the detection plate has no red spot, and the result is negative.
[ REFERENCE VALUES (REFERENCE RANGE) ]
Based on the normal reference range of the H factor antigen determination kit, the H factor antigen content is 274 mg/L-508 mg/L, no red spot exists at the center detection point of the reaction hole of the detection plate in the normal reference range of the H factor antigen content of the sample, and a negative result is displayed;
normal reference range: negative results were shown (indicating that the antigen content of factor H was between 274mg/L and 508 mg/L).
[ interpretation of test results ]
1. Negative result, indicating that the H factor antigen content of the sample is 274 mg/L-508 mg/L which is a normal range;
2. a positive result indicates that the H factor antigen content > 508mg/L in the sample is in an abnormal range.
[ limitations of assay methods ]
1. The method can only qualitatively determine the H factor in the human serum sample and is only used as auxiliary diagnosis;
2. stability of reaction spots: within 30 minutes the positive spots did not fade and the negative results remained unchanged.
20 examples of detection results: (patients with cerebral thrombosis, cerebral infarction, cerebral hemorrhage, and cerebral embolism)
Figure BDA0002573449350000051
Figure BDA0002573449350000061
20 healthy persons (all negative in liver function, kidney function, HBsAg, HIV, hepatitis C, etc.) were negative between 274mg/L and 508 mg/L.
Negative of Negative of Negative of Negative of Negative of
Negative of Negative of Negative of Negative of Negative of
Negative of Negative of Negative of Negative of Negative of
Negative of Negative of Negative of Negative of Negative of
Results of 4 patients of 20 cases of heart or cerebral thrombosis, heart or cerebral infarction, cerebral hemorrhage and heart or cerebral embolism are compared with results of 20 healthy patients, and the clinical diagnosis is completely met.
Results from 60 of 10 tumor patients: (thyroid cancer, liver cancer, stomach cancer, uterine cancer, cervical cancer, lung cancer, breast cancer, esophageal cancer, nasopharyngeal cancer, prostate cancer, colorectal cancer, kidney cancer, pancreatic cancer, bladder cancer)
Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for
Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for
Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for
Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for
Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for
Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for Positive for
Example 2: immune latex turbidimetry kit
The instrument comprises the following steps: 7100 Biochemical instrument
The operation method comprises the following steps: the samples were assayed using Hitachi 7100 Biochemical Analyzer. In the step of measuring the sample by using a biochemical analyzer, after the sample is added with the reagent I R1, the sample is incubated at 37 ℃ for 5min, the sample A1 at the 1 st point is read, the reagent II R2 is added, the sample is incubated at 37 ℃ for 5min, the sample A2 at the 2 nd point is read, and the sample A is sample A2-sample A1; the method also comprises a step of measuring the calibrator by using a Hitachi 7100 biochemical analyzer, wherein in the step of measuring the calibrator by using the biochemical analyzer, the calibrator is added into a reagent I R1, then the mixture is incubated at 37 ℃ for 5min, the calibrator A1 at the 1 st point is read, the reagent II R2 is added, the mixture is incubated at 37 ℃ for 5min, and the calibrator A2 at the 2 nd point is read, wherein the calibrator A is calibrator A2-calibrator A1;
Figure BDA0002573449350000071
the parameters measured above were: temperature 37 ℃, wavelength 600nm, R1: 160uLR 2: 40 uL. Sample or calibrator 3 μ l, R1: 240 μ l, R2: 60 μ l, reaction time 10 min.
20 normal persons (negative for liver function, kidney function, HBsAg, HIV, hepatitis C, etc.)
301mg/L 362mg/L 465mg/L 496mg/L 299mg/L
289mg/L 418mg/L 378mg/L 483mg/L 455mg/L
449mg/L 450mg/L 321mg/L 340mg/L 436mg/L
345mg/L 372mg/L 335mg/L 367mg/L 492mg/L
Concentrations between 274mg/L and 508mg/L are normal.
The clinical diagnosis results of 20 healthy people are between 274mg/L and 508mg/L, are negative and meet the clinical diagnosis standard.
60 cases of tumor patients (thyroid cancer, liver cancer, stomach cancer, uterine cancer, cervical cancer, lung cancer, breast cancer, esophageal cancer, nasopharyngeal cancer, prostate cancer, colorectal cancer, kidney cancer, pancreatic cancer, bladder cancer)
Figure BDA0002573449350000072
Figure BDA0002573449350000081
Concentrations between 274mg/L and 508mg/L are normal.
The results of 60 cases of clinical diagnosis are below 274mg/L or above 508mg/L, are positive and accord with the clinical diagnosis standard.
Example 3: 20 samples of cerebral hemorrhage (immunoturbidimetry)
The instrument comprises the following steps: 7100 Biochemical instrument
The operation method is the same as that of example 2
Figure BDA0002573449350000082
Kit parameters: wavelength 600nm, R1: 160uLR 2: 40 uL.
20 examples of detection results:
641mg/L 540mg/L 746mg/L 520mg/L 563mg/L
537mg/L 568mg/L 666mg/L 674mg/L 614mg/L
556mg/L 655mg/L 539mg/L 632mg/L 695mg/L
732mg/L 775mg/L 547mg/L 595mg/L 632mg/L
concentrations between 274mg/L and 508mg/L are normal.
The clinical diagnosis result of 20 patients with cerebral hemorrhage is more than 508mg/L, is positive and accords with the clinical diagnosis standard.
Example 4: 20 samples of cardiac or cerebral infarction (immunoturbidimetry)
The instrument comprises the following steps: 7100 Biochemical instrument
The operation method is the same as that of example 2
Figure BDA0002573449350000091
Parameters are as follows: wavelength 340nm, R1: 160uLR 2: 40 uL.
20 cases of test results
662mg/L 543mg/L 545mg/L 612mg/L 646mg/L
575mg/L 679mg/L 564mg/L 707mg/L 671mg/L
615mg/L 589mg/L 694mg/L 585mg/L 862mg/L
762mg/L 704mg/L 605mg/L 584mg/L 596mg/L
Concentrations between 274mg/L and 508mg/L are normal.
The clinical diagnosis result of 20 patients with cardiac or cerebral infarction is more than 508mg/L, is positive and meets the clinical diagnosis standard.
Example 5: 20 samples of cardiac or cerebral thrombosis (immunoturbidimetry)
The instrument comprises the following steps: 7100 Biochemical instrument
The operation method is the same as that of example 2
Figure BDA0002573449350000092
Parameters are as follows: wavelength 600nm, R1: 160uLR 2: 40 uL.
20 cases of test results
Figure BDA0002573449350000093
Figure BDA0002573449350000101
Concentrations between 274mg/L and 508mg/L are normal.
The clinical diagnosis result of 20 patients with cardiac or cerebral thrombosis is more than 508mg/L, is positive and accords with the clinical diagnosis standard.
Example 6: 20 samples of cardiac or cerebral embolism (immunoturbidimetry)
The instrument comprises the following steps: 7100 Biochemical instrument
The operation method is the same as that of example 2
Figure BDA0002573449350000102
Parameters are as follows: wavelength 600nm, R1: 160uL R2: 40 uL.
20 examples of detection results:
550mg/L 606mg/L 846mg/L 518mg/L 540mg/L
663mg/L 678mg/L 539mg/L 648mg/L 675mg/L
606mg/L 702mg/L 550mg/L 623mg/L 528mg/L
877mg/L 735mg/L 545mg/L 590mg/L 514mg/L
concentrations between 274mg/L and 508mg/L are normal.
The clinical diagnosis result of 20 patients with cardiac or cerebral embolism is more than 508mg/L, is positive and meets the clinical diagnosis standard.
Example 7: 20 examples chemiluminescence method
The chemiluminescence detection method comprises the following steps:
1. the instrument comprises the following steps: MPC-1 chemiluminescence determinator
2. Fixing the anti-human H factor antibody on the surface of a solid phase, adding a sample to be detected and a marked anti-human H factor antibody, incubating, and then washing with a washing solution; meanwhile, setting a reference of the H factor standard substance;
3. adding a chemiluminescent substrate working solution, and standing for a period of time;
4. and measuring the luminous value to obtain the H factor concentration value of the sample to be measured.
20 examples of detection results: 20 patients with cardiac or cerebral infarction
586mg/L 750mg/L 619mg/L 595mg/L 855mg/L
563mg/L 774mg/L 605mg/L 653mg/L 646mg/L
615mg/L 584mg/L 771mg/L 840mg/L 673mg/L
652mg/L 616mg/L 665mg/L 744mg/L 846mg/L
Concentrations between 274mg/L and 508mg/L are normal.
The results of 20 cases of clinical diagnosis are more than 508mg/L, are positive and accord with the clinical diagnosis standard.
Example 8: specimens of 50 gram-positive bacteria, gram-negative bacteria and viral infections (chemiluminescence method)
Results of 50 cases
Figure BDA0002573449350000111
Concentrations between 274mg/L and 508mg/L are normal.
The clinical diagnosis result of 50 cases of patients infected by gram-positive bacteria, gram-negative bacteria and viruses is more than 508mg/L, is positive and accords with the clinical diagnosis standard.
The above examples of the present invention are merely examples for clearly illustrating the present invention and are not intended to limit the embodiments of the present invention. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. Any modification, equivalent replacement, and improvement made within the spirit and principle of the present invention should be included in the protection scope of the claims of the present invention.

Claims (8)

  1. Use of a factor H antibody in the preparation of a kit for detecting peripheral serum, whole blood or peripheral blood for diagnosing heart or cerebral thrombosis, heart or cerebral infarction, cerebral hemorrhage, heart or cerebral embolism, bacterial infection, viral infection or tumor.
  2. 2. Use according to claim 1, characterized in that: the tumor is thyroid cancer, liver cancer, gastric cancer, uterine cancer, cervical cancer, lung cancer, breast cancer, esophageal cancer, nasopharyngeal cancer, prostatic cancer, colon cancer, rectal cancer, renal cancer, pancreatic cancer or bladder cancer.
  3. 3. Use according to claim 1, characterized in that: the kit comprises a detection plate, a rabbit anti-H factor antibody, a goat anti-H factor antibody conjugate marked by colloidal gold, a sealing liquid, a washing liquid, a positive reference product and a negative reference product, wherein the detection plate consists of a plastic box bottom box, a water absorption layer is arranged in the plastic box bottom box, a nitrocellulose membrane is arranged on the water absorption layer, a filter screen is covered on the nitrocellulose membrane, a plastic box surface cover is arranged on the filter screen, a detection reaction hole is arranged in the center of the plastic box surface cover, the rabbit anti-H factor antibody and the goat anti-H factor antibody conjugate marked by the colloidal gold are dotted on the nitrocellulose membrane corresponding to the detection reaction hole, the sealing liquid is a phosphate solution containing bovine serum albumin, the pH value of the phosphate solution is 7.0-7.5, and the weight percentage of the bovine serum albumin in the phosphate solution is 1.0%, the washing solution is a Tris-HCl solution containing Tween-20, the pH of the Tris-HCl solution is 7.0-7.5, the weight percentage of the Tween-20 in the Tris-HCl solution is 0.05%, the mass of the goat anti-H factor antibody in each milliliter of colloidal gold conjugate is 700 mg, and the positive reference substance is the H factor antigen with the concentration of more than 508 mg/L.
  4. 4. Use according to claim 1, characterized in that: and (3) adopting a colloidal gold percolation method and a chromatography method or a chemiluminescence method for detection.
  5. 5. Use according to claim 1, characterized in that: and performing clinical examination and routine detection by adopting an ELISA method, an immunoturbidimetry method, an immunotransmission turbidimetry method, an immunoscattering turbidimetry method or an immunolatex enhanced turbidimetry method.
  6. 6. Use according to claim 1, characterized in that: and detecting by adopting a micro-fluidic chip.
  7. 7. Use according to claim 1, characterized in that: the rabbit anti-H factor antibody is a monoclonal antibody or a polyclonal antibody.
  8. 8. A kit, characterized in that: detection was performed using a factor H antigen-antibody binding reaction.
CN202010646848.7A 2020-07-07 2020-07-07 Application of H factor antibody in preparation of detection kit Pending CN111751555A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010646848.7A CN111751555A (en) 2020-07-07 2020-07-07 Application of H factor antibody in preparation of detection kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010646848.7A CN111751555A (en) 2020-07-07 2020-07-07 Application of H factor antibody in preparation of detection kit

Publications (1)

Publication Number Publication Date
CN111751555A true CN111751555A (en) 2020-10-09

Family

ID=72679927

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010646848.7A Pending CN111751555A (en) 2020-07-07 2020-07-07 Application of H factor antibody in preparation of detection kit

Country Status (1)

Country Link
CN (1) CN111751555A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054271A1 (en) * 2003-03-20 2007-03-08 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
CN102633882A (en) * 2011-02-14 2012-08-15 中国医学科学院基础医学研究所 Protein complex and application of protein complex in tumor diagnosis and/or prognosis evaluation
CN105548558A (en) * 2015-12-11 2016-05-04 北京大学第一医院 Method, device and kit for detecting concentration of factor H
CN107505458A (en) * 2015-11-16 2017-12-22 李乔利 A kind of composition that can detect stomach cancer, liver cancer, colon cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054271A1 (en) * 2003-03-20 2007-03-08 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
CN102633882A (en) * 2011-02-14 2012-08-15 中国医学科学院基础医学研究所 Protein complex and application of protein complex in tumor diagnosis and/or prognosis evaluation
CN107505458A (en) * 2015-11-16 2017-12-22 李乔利 A kind of composition that can detect stomach cancer, liver cancer, colon cancer
CN105548558A (en) * 2015-12-11 2016-05-04 北京大学第一医院 Method, device and kit for detecting concentration of factor H

Similar Documents

Publication Publication Date Title
CN102072957B (en) Hepatitis C virus antibody diagnostic kit and preparation method thereof
CN104749009B (en) immunosuppressant drug extraction reagent for immunoassay
CN112858675B (en) Novel coronavirus antigen and antibody combined intelligent detection device
CN110275028B (en) Colloidal gold-labeled anti-HE4 antibody kit and preparation method thereof
CN101339190A (en) Human body important parasite antigen chip and method for making same
KR100844169B1 (en) A Hepatitis C Antigen-Antibody Combination Assay for the Early Detection of HCV Infection
CN110850085A (en) Abnormal prothrombin chemiluminescence immunoassay kit and preparation method thereof
CN106855573A (en) Detection PSA spot gold diafiltration kit and its detection method
CN105424941B (en) AKR1B10 albumen and the kit for liver cirrhosis diagnosis
CN111751555A (en) Application of H factor antibody in preparation of detection kit
CN107490693A (en) A kind of fluorescence immune chromatography method for quantitatively detecting cardiac muscle troponin I and cardic fatty acid binding protein
EP2009444B1 (en) Non-invasive test method for non-alcoholic steatohepatitis based on cytochrome-c quantification
EP2584361A1 (en) Marker for detection and/or discrimination of non-alcoholic steatohepatitis, method for detection and/or discrimination of non-alcoholic steatohepatitis, and kit for use in the method
CN109187943B (en) Anti-interference reagent cup and preparation method of anti-interference coating in reagent cup
CN111693700A (en) Use of factor B antibodies in preparation of detection kit
JPH0580053A (en) Immunochemical detection method for human corpus uteri cancer cell
CN111751556A (en) Application of C3 antibody in preparation of detection kit
CN111693699A (en) Application of C4 antibody in preparation of detection kit
Kim et al. A qualitative agar gel immunoprecipitin (IP) test for detection of fecal occult human hemoglobin
US20210389326A1 (en) Method for detecting viral liver cancer
CN114487410A (en) Application of H factor antibody in preparation of kit for detecting hemodialysis, peritoneal dialysis, peritonitis or glioma
CN106483298B (en) Chemiluminescence immunoassay kit for detecting cytokeratin 19 fragment
CN111239410A (en) Kit for detecting liver cancer, hepatitis and/or liver cirrhosis and application of kit in AKR1B10 and AFP combined quantitative determination
CN111693698A (en) Application of complement C1q antibody in preparation of detection kit
CN111562374A (en) New application of glucose 6 phosphate isomerase kit

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination